MedTrace Logo

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

NCT03142165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2018-01-12

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.

Conditions

Interventions

DRUG

BMS-986263

3 weekly doses of 90 mg infused intravenous administration

OTHER

Placebo

Placebo

DRUG

Diphenhydramine

50 mg intravenous administration

DRUG

Famotidine

20 mg intravenous administration

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-11
Primary Completion
2017-11-29
Completion
2017-11-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03142165 on ClinicalTrials.gov